Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-03 00:33 | 2025-12-01 | LQDA | Liquidia Corp | Krepp Sarah | Officer | SELL | $32.19 | 221 | $7,114 | 141,218 |
| 2025-12-03 00:31 | 2025-12-01 | LQDA | Liquidia Corp | Boyle Dana | Officer | SELL | $32.19 | 303 | $9,754 | 155,031 |
| 2025-12-03 00:30 | 2025-12-01 | LQDA | Liquidia Corp | Moomaw Scott | Officer | OPT+S | $32.19 | 831 | $26,750 | 154,506 |
| 2025-12-03 00:31 | 2025-12-01 | LQDA | Liquidia Corp | Adair Jason | Officer | OPT+S | $32.19 | 693 | $22,308 | 175,868 |
| 2025-12-03 00:32 | 2025-12-01 | LQDA | Liquidia Corp | Kaseta Michael | Officer | OPT+S | $32.19 | 1,166 | $37,534 | 353,823 |
| 2025-12-03 01:14 | 2025-12-01 | XERS | Xeris Biopharma Holdings, Inc. | Hecht Beth | Officer | SELL | $7.01 | 16,667 | $116,781 | 1,320,176 |
| 2025-12-03 00:15 | 2025-11-28 | BMEA | Biomea Fusion, Inc. | Erdtmann Rainer M | Director, Officer | BUY | $1.09 | 50,000 | $54,550 | 693,027 |
| 2025-12-03 00:43 | 2025-11-28 | PBH | Prestige Consumer Healthcare Inc. | Zerillo Jeffrey | Officer | SELL | $60.00 | 1,000 | $60,000 | 42,048 |
| 2025-12-03 00:04 | 2025-12-01 | MIRM | Mirum Pharmaceuticals, Inc. | GREY MICHAEL G | Director | OPT+S | $74.00 | 50,000 | $3,700,000 | 0 |
| 2025-12-03 03:00 | 2025-12-01 | GNLX | GENELUX Corp | Thomas John | Director | SELL | $5.00 | 10,000 | $50,008 | 492,784 |
| 2025-12-03 00:31 | 2025-12-01 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $479.91 | 22,500 | $10,798,079 | 0 |
| 2025-12-03 00:32 | 2025-12-01 | UTHR | UNITED THERAPEUTICS Corp | EDGEMOND JAMES | Officer | OPT+S | $479.99 | 21,000 | $10,079,696 | 8,142 |
| 2025-12-03 00:32 | 2025-12-01 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $481.61 | 8,000 | $3,852,846 | 130 |
| 2025-12-03 00:15 | 2025-11-28 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $42.10 | 7,040 | $296,376 | 26,800 |
| 2025-12-03 01:14 | 2025-12-02 | CYTK | CYTOKINETICS INC | HENDERSON JOHN T | Director | OPT+S | $63.90 | 8,750 | $559,125 | 74,578 |
| 2025-12-03 01:10 | 2025-12-02 | CYTK | CYTOKINETICS INC | Malik Fady Ibraham | Officer | OPT+S | $63.89 | 2,200 | $140,558 | 140,610 |
| 2025-12-02 17:18 | 2025-12-01 | CYTK | CYTOKINETICS INC | Kaye Edward M. MD | Director | OPT+S | $66.72 | 28,064 | $1,872,430 | 9,977 |
| 2025-12-02 17:13 | 2025-12-01 | CYTK | CYTOKINETICS INC | Harrington Robert Arthur | Director | SELL | $66.80 | 2,150 | $143,620 | 18,542 |
| 2025-12-01 14:20 | 2025-11-26 | MAIA | MAIA Biotechnology, Inc. | Vitoc Vlad | Director, Officer, 10% owner | BUY | $1.11 | 72,000 | $79,848 | 853,421 |
| 2025-12-01 14:18 | 2025-11-26 | MAIA | MAIA Biotechnology, Inc. | Luput Cristian | Director | BUY | $1.10 | 38,145 | $41,845 | 437,628 |
| 2025-12-01 14:14 | 2025-11-26 | MAIA | MAIA Biotechnology, Inc. | Smith Stan | Director | BUY | $1.04 | 15,000 | $15,582 | 1,364,289 |
| 2025-12-01 16:56 | 2025-11-28 | KTTA | Pasithea Therapeutics Corp. | Marques Tiago | Director, Officer | BUY | $0.75 | 33,333 | $25,000 | 73,334 |
| 2025-12-01 16:54 | 2025-11-28 | KTTA | Pasithea Therapeutics Corp. | Dumesnil Simon | Director | BUY | $0.75 | 33,333 | $25,000 | 35,833 |
| 2025-12-02 00:17 | 2025-11-26 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | Officer | OPT+S | $30.10 | 5,000 | $150,487 | 171,928 |
| 2025-12-02 00:37 | 2025-11-26 | KNSA | Kiniksa Pharmaceuticals International, plc | Tessari Eben | Officer | OPT+S | $42.89 | 200 | $8,578 | 22,714 |
| 2025-12-02 02:09 | 2025-11-26 | RCUS | Arcus Biosciences, Inc. | Azoy Alexander | Officer | OPT+S | $26.00 | 1,900 | $49,400 | 27,363 |
| 2025-12-02 00:57 | 2025-11-26 | ONC | BeOne Medicines Ltd. | Sanders Corazon (Corsee) D. | Director | OPT+S | $340.90 | 2,627 | $895,534 | 0 |
| 2025-12-02 02:12 | 2025-11-26 | HOWL | Werewolf Therapeutics, Inc. | MPM BioVentures 2014, L.P. | 10% owner | SELL | $0.96 | 141,927 | $136,860 | 4,983,843 |
| 2025-12-02 00:40 | 2025-11-26 | VSTM | Verastem, Inc. | Paterson Dan | Director, Officer | SELL | $10.50 | 6,000 | $63,000 | 426,818 |
| 2025-12-02 01:41 | 2025-12-01 | ALKS | Alkermes plc. | Hopkinson Craig C. | Officer | SELL | $29.30 | 4,000 | $117,200 | 65,740 |
| 2025-12-02 02:10 | 2025-11-28 | ARWR | Arrowhead Pharmaceuticals Inc. | Ferrari Mauro | Director | SELL | $56.39 | 8,750 | $493,413 | 68,764 |
| 2025-12-02 00:02 | 2025-11-26 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | MIGNONE ROBERTO | Director | SELL | $26.03 | 50,000 | $1,301,505 | 445,000 |
| 2025-12-02 03:02 | 2025-11-26 | TBPH | Theravance Biopharma, Inc. | BROSHY ERAN | Director | OPT+S | $20.00 | 29,501 | $590,020 | 44,703 |
| 2025-12-02 02:09 | 2025-11-26 | ALMS | Alumis Inc. | AKKARAJU SRINIVAS | Director | BUY | $7.55 | 173,589 | $1,310,684 | 816,849 |
| 2025-12-02 00:15 | 2025-11-26 | JNJ | JOHNSON & JOHNSON | MORIKIS JOHN G | Director | BUY | $206.15 | 1,250 | $257,688 | 1,849 |
| 2025-12-02 02:14 | 2025-11-26 | JAZZ | Jazz Pharmaceuticals plc | COZADD BRUCE C | Director | OPT+S | $177.81 | 77,500 | $13,780,337 | 393,332 |
| 2025-12-02 02:13 | 2025-11-26 | HOWL | Werewolf Therapeutics, Inc. | EVNIN LUKE | Director | SELL | $0.96 | 91,088 | $87,836 | 3,196,463 |
| 2025-12-02 02:11 | 2025-11-26 | HOWL | Werewolf Therapeutics, Inc. | GADICKE ANSBERT | 10% owner | SELL | $0.96 | 141,927 | $136,860 | 4,983,843 |
| 2025-12-01 17:07 | 2025-11-28 | KTTA | Pasithea Therapeutics Corp. | STEINMAN LAWRENCE | Director | BUY | $0.75 | 133,333 | $100,000 | 199,691 |
| 2025-12-02 00:31 | 2025-11-26 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $486.34 | 8,000 | $3,890,754 | 130 |
| 2025-11-29 01:51 | 2025-11-25 | IONS | IONIS PHARMACEUTICALS INC | Devers Shannon L. | Officer | OPT+S | $80.91 | 16,777 | $1,357,442 | 17,494 |
| 2025-11-28 14:52 | 2025-11-25 | MAIA | MAIA Biotechnology, Inc. | Luput Cristian | Director | BUY | $0.98 | 10,000 | $9,785 | 399,483 |
| 2025-11-28 14:48 | 2025-11-25 | MAIA | MAIA Biotechnology, Inc. | Vitoc Vlad | Director, Officer, 10% owner | BUY | $0.97 | 10,500 | $10,144 | 831,421 |
| 2025-11-28 14:05 | 2025-11-25 | GLSI | Greenwich LifeSciences, Inc. | Patel Snehal | Director, Officer, 10% owner | BUY | $8.37 | 4,600 | $38,502 | 5,588,102 |
| 2025-11-29 00:05 | 2025-11-25 | MRUS | Merus N.V. | Shuman Harry | Officer | OPT+S | $95.92 | 8,300 | $796,136 | 11,002 |
| 2025-11-28 17:00 | 2025-11-26 | COCP | Cocrystal Pharma, Inc. | FROST PHILLIP MD ET AL | Director, 10% owner | BUY | $0.99 | 4,000 | $3,975 | 1,703,551 |
| 2025-11-29 01:00 | 2025-11-26 | CPRX | CATALYST PHARMACEUTICALS, INC. | Del Carmen Jeffrey | Officer | OPT+S | $23.33 | 10,983 | $256,244 | 3,962 |
| 2025-11-29 01:51 | 2025-11-25 | IONS | IONIS PHARMACEUTICALS INC | KLEIN JOSEPH III | Director | OPT+S | $80.00 | 12,000 | $960,000 | 0 |
| 2025-11-29 01:38 | 2025-11-25 | BHC | Bausch Health Companies Inc. | PAULSON & CO. INC. | 10% owner | BUY | $6.25 | 2,500,000 | $15,625,000 | 73,255,869 |
| 2025-11-27 00:00 | 2025-11-25 | LLY | ELI LILLY & Co | LILLY ENDOWMENT INC | 10% owner | SELL | $1,109.30 | 15,632 | $17,340,624 | 92,196,978 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.